John M. Gill – Founder, President, Chief Executive Officer and Director
Mr. Gill was Chief Operating Officer and a member of the Board of Directors of 3-Dimensional Pharmaceuticals, Inc. (3DP) until May 2003. He joined 3DP in May 2001 as Executive Vice President and Chief Financial Officer.  From 1995 to 2001, Mr. Gill was Vice President and Director, Operations and Finance, SmithKline Beecham Research and Development, now GlaxoSmithKline plc where he was a member of the R&D Executive Committee and Chairman of the R&D Operating Committee.  From 1985 to 1995 Mr. Gill served as a founding member and partner in SR One, Limited, SmithKline Beecham’s Life Sciences Venture Capital Fund. 

Mark A. McKinlay, PhD - Chief Scientific Officer
Dr. McKinlay was a founder and Vice President of R&D ViroPharma Corporation, a company focused on the discovery and development of drugs to treat RNA viral infections from 1994 to 2004.   From 1985 to 1994, Dr. McKinlay held a variety of drug discovery and development senior director positions in virology and oncology at Sterling Winthrop Pharmaceuticals Research Division.  He was a post-doctoral fellow in the Division of Biophysics at the Johns Hopkins School of Public Health from 1978 to 1980 and received his Ph.D. in biology from the Rensselaer Polytechnic Institute during 1978.

Martin A. Graham, PhD - Vice President, Preclinical Development
Dr. Graham was a founder of PKPD Incorporated, a clinical pharmacology research and development organization.  Prior to founding PKPD Inc., he had been Vice President of Development at Gemin X Biotechnologies, a Canadian based Oncology Drug Discovery and Development Company, Director of Pharmacokinetics at Centocor Inc. and Associate Director of Pharmacokinetics at Sanofi-Synthelabo Pharmaceuticals where he was responsible for the pharmacokinetics and clinical pharmacology sections of the Oxaliplatin, Urate Oxidase, Mitguazone and Alfuzosin MAA and NDA submissions. Martin received his Ph.D. in pharmacology at the Institute of Cancer Research at the Royal Marsden Hospital, University of London, England and conducted post doctoral research at the Beatson Institute, University of Glasgow, Scotland where he headed the pharmacokinetics group.

James E. Goldschmidt, PhD - Vice President, Commercial Development
Dr. Goldschmidt was Executive Director of Business Development and New Oncology Products for Johnson & Johnson until March 2007.  Prior to J&J, he held several senior positions at Wyeth Pharmaceuticals from 1997 to 2004 including Executive Director of Oncology New Business and Chair of the Oncology Therapeutic Area Leadership Team.  Jim started his pharmaceutical career at SmithKline Beecham, now GlaxoSmithKline plc, where he held positions of increasing responsibility in regulatory, strategic product development and brand marketing for the oncology and specialty pharmaceuticals groups.  Jim received his Ph.D. in pharmacology from Temple University School of Medicine.

Christine M. Debouck, PhD - Necrostatin Program Head
Dr. Debouck is currently President of Ardennes Biosciences LLC, a genomics and pharmaceuticals consulting company.  She was formerly Senior VP in R&D at GlaxoSmithKline, and is renowned for her expertise in target validation, disease understanding and compound characterization as well as for her broad applications of biotechnology, genomics and biomarker discovery in pre-clinical and clinical development.  Dr. Debouck brings 24 years of experience in directing creative science in diverse areas of pharmaceutical research.  She received her Ph.D. summa cum laude from the University of Brussels-Belgium, Department of Genetics.  As a bench scientist in SmithKline & French, she made critical contributions to the field of AIDS research, and was the first to report the identification of the HIV protease and its proteolytic activity as a therapeutic target in the treatment of AIDS.  Later in SB and GSK, she was one of the first pharmaceutical industry senior scientists to drive applications of high throughput gene discovery to the identification of novel therapeutic targets.  As SVP in GSK, she integrated genomics into cross-therapeutic drug discovery and drug development activities.  Dr. Debouck has authored over 115 publications, and holds 16 issued patents.  In 2003, she was appointed to the Scientific Board of the Bill & Melinda Gates Foundation ‘Grand Challenges for Global Health’ initiative.

Peter O’Dwyer, MD - Clinical and Regulatory Advisor
Dr. O’Dwyer received an M.B., B.Ch at the University of Dublin, Trinity College.  After residencies in pediatrics and internal medicine, he was a Fellow at the Baltimore Cancer Research Center, and then a Senior Investigator at the Investigational Drug Branch, Cancer Therapy Evaluation Program, of the National Cancer Institute. Dr. O’Dwyer is presently Professor of Medicine at the University of Pennsylvania, and Director of the Experimental Therapeutics Program in the Abramson Cancer Center of the University of Pennsylvania.  He is Vice Chairman of the Eastern Cooperative Oncology Group and Co-Chair of the Gastrointestinal Committee. Dr. O’Dwyer has extensive clinical experience with the chemotherapy of colorectal cancer and with antiangiogenesis therapies.

Stephen Condon, PhD - Director, Medicinal Chemistry
Dr. Condon joined TetraLogic Corporation in 2004 as the leader of the Chemistry Group and has been involved in the discovery of inhibitors of the Smac-XIAP protein-protein interaction for the treatment of human cancers.  From 2001-2004, he was a Group Leader of the medicinal chemistry group at ViroPharma, Inc.  Prior to ViroPharma, Dr. Condon worked in the medicinal chemistry group at Rhône-Poulenc Rorer. He received his Ph.D. with Professor Amos B. Smith, III at the University of Pennsylvania in 1994 where he completed the total syntheses of rapamycin and demethoxyrapamycin.

Srinivas Chunduru, PhD - Director, Biology
Dr. Chunduru joined TetraLogic in May of 2004 as the leader of the Biology Team.  Prior to TetraLogic, he was a Group Leader of biology at ViroPharma, Inc.  Prior to ViroPharma, Dr. Chunduru was a NIH fellow at the University of Pennsylvania from 1993 to 1996 and a postdoctoral fellow at St. Jude’s Children’s Hospital from 1990 to 1993.  He received his Ph.D. from the University of Akron in 1991.